Because the level of ErbB2 gene amplification in ErbB2 positive cancers is much higher than in normal tissue, targeted inactivation of the ErbB2 protein evolved as one to the most promising and successful antineoplastic strategies in these cancers. Here, ERBB2 is linked to cancer.